This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Dr. Beutner earned his B.S. in Biology from Saint Mary's College in 1971. Dr. Beutner also holds an M.A. and Ph.D. in Microbiology and Immunology and an M.D. from the State University of New York at Buffalo School of Medicine. Following medical school, he was an intern and resident in pediatrics at UCLA, a fellow in infectious diseases and immunology and a resident in dermatology at the University of Rochester. Following residency in 1985 Dr. Beutner founded Solano Dermatology Associates, a general and specialty dermatology practice in Northern California, which included the creation of two clinical research centers conducting over 350 phase 1, 2, and 3 clinical trials. His first position in industry was as Medical Director of Oclassen Pharmaceuticals. After years of managing the clinical trail units, consulting with small and large pharmaceutical and biotechnology companies in 2001, he merged the Solano Dermatology Associates clinical trial units with Dow Pharmaceutical Sciences, a contract research organization and development company specializing in topical formulations and product development. He was Dow's Chief Medical Officer managing clinical trials, supporting internal development programs, and consulting with clients. He left Dow in 2005 to become Senior VP and Chief Medical Officer at Anacor Pharmaceuticals, a boron chemistry-based company dedicated to the discovery and development of new drugs to treat skin diseases. After leaving Anacor in 2010, he served as Chief Medical Officer of a number of small start-up dermatology companies including Novan, Rogne Biosciences, Chromaderm, SeylanMed, Nflexion, and Pellapharm. In 2017 he co-founded Dermbiont, a company discovering and developing microbiome based products and targeted small molecules to treat, cure, and prevent skin diseases. He has had a major leadership role in programs that have produced over a dozen approved and marketed products. He continues to maintain a part-time practice of general dermatology at Solano Dermatology Associates in Fairfield, CA.
In addition, Dr. Beutner served as an Associate Clinical Professor of Dermatology at the University of California, San Francisco for several decades. Dr. Beutner was a member of the advisory committee for the American Social Health Association's Scientific Advisory Board on human papillomavirus. He served on the American Academy of Dermatology Therapeutics/FDA Liaison Task Force and as the chair of the academy's treatment guidelines committee, helping with the transition from opinion based to evidence based practice guidelines. He is a past president of the Solano County Medical Society and the San Francisco Dermatological Society. Dr. Beutner was the founding chairman of the School of Science Advisory Board of Saint Mary's College of California and was elected to the college&s;s Board of Trustees in 2019. Dr. Beutner and his wife, Mary, have three grown children, all of whom have attended Saint Mary's College, and all have biomedical related careers. In the past 3 years the Beutners have welcomed their first 4 grandchildren.
Ken Cacciatore is a Managing Director and senior research analyst at Cowen. He joined the Cowen pharmaceutical research team in 2000 and prior to that he worked in Cowen’s health care investment banking department, which he joined in 1995. Mr. Cacciatore graduated from Lafayette College with a degree in Economics and received an MBA from the Anderson School at UCLA.
Ms. Cronholm has more than 25 years' experience in the life sciences and medical device industry. She managed the body contouring franchise at Cynosure, directing marketing and product management of several aesthetic product lines for treatment of cellulite and fat reduction. She has a track record of launching exceptionally successful products and building commercial teams while spearheading operational improvements to drive productivity and increase value for the company. Previously, Karen was Head of Marketing for the Lab Solutions business at EMD Millipore. Through her 12 year tenure at EMD Millipore she successfully developed many new technologies, held various roles such as marketing manager, research and development scientist, and quality manager. She began her career in the biotech industry working with TransKaryotic Therapies. Karen has a B.S. in Microbiology from the University of New Hampshire and earned an M.B.A. with honors from Northeastern University
Tobin Dickerson joined MiNDERA from The Scripps Research Institute where he was an Associate Professor in the Department of Chemistry and the Worm Institute for Research and Medicine from 2005-2019. He completed his BS with high honors in Chemistry from the University of Virginia in 1999, and subsequently was awarded his MA in Chemistry in 2000. At that time, he matriculated to TSRI where he completed his PhD in 2004 in Chemical Biology. Toby was promoted to the TSRI faculty in 2005 where he has established a research program aimed at developing disruptive platform technologies for problems of emergent clinical significance. In addition to the MiNDERA technology platform, his laboratory has developed technologies that allow for the prediction of protein evolution, a universal screening system for protein-ligand interactions, and a metabolomics platform for the diagnosis of infectious disease in resource-limited areas.
Toby has >85 publications, and has served as PI of both governmentally and corporately sponsored research from small biotech companies as well as major pharmaceutical firms. His scientific expertise includes diagnostic platform development, small molecule and vaccine discovery, metabolomics, scientific algorithm and software development, phage display, and neglected tropical diseases.
Tim Holt is President and CEO of R2 Technologies headquartered in San Ramon, California. R2 is currently developing breakthrough CryoAesthetic technologies that will launch in the US and China markets in early 2021. Tim has 17 years of commercial experience in the aesthetic medical device industry which includes key leadership roles at Reliant Technologies and ZELTIQ. He was at the forefront of the successful product launches of Fraxel and CoolSculpting as well as the growth and scaling of those two ventures from start-up to IPO/acquisition. R2 will be Tim's third successive company delivering a game-changing product to market that originated in the labs of world-renowned serial inventors, Drs. Rox Anderson, Dieter Manstein and Henry Chan.
Tim is a native of Ohio. He received his BBA in Marketing from Ohio University in 1997 and his MBA from Campbell University in 1999. He has been involved in various youth mentorship roles and philanthropic organizations. He is a member of the Ohio University Executive Advisory Board, he’s a sponsor of the Ohio University Select Leaders Program and he’s an Ambassador for the Gratitude Network.
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015.
During Mr. Hoppenot's tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & AutoImmunity. Under his leadership, revenue has increased by over 500 percent, which includes the addition of 5 new sources of potential revenue and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in Canada, 10 European countries, Japan and China.
Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.
Michael Howell is the Chief Scientific Officer at DermTech where they focus on precision and personalized approaches to dermatology. Prior to DermTech, Dr. Howell was a faculty member at National Jewish Health, and held roles of increasing responsibility at Boehringer Ingelheim, Immune Tolerance Network, MedImmune/AstraZeneca, and the Incyte Corporation. Dr. Howell has previously led research and development teams dedicated to the discovery of novel therapies for dermatology and the integration of novel biomarker approaches into clinical development. His efforts have led to the approval of multiple therapies, novel diagnostic approaches to patient treatment, and have been highlighted in more than 50 publications and numerous patents. Dr. Howell received his PhD in Immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health.
Niquette Hunt is an entrepreneur and successful executive with over 25 years of general management experience. Coming out of line management in both large corporations and start-ups (P&G, Warner Lambert, Revance Therapeutics, Amira Medical) Ms. Hunt has proven her ability to drive significant growth on a variety of businesses across multiple industries. She has successfully launched over twenty new products and every brand she has managed has increased in sales, market share and/or profits under her watch.
She founded Candesant Biomedical in 2016 with the goal of alleviating the suffering of the 84 million people in the US who sweat too much. Candesant will provide a safe, efficacious and cost-effective solution for these individuals who represent a potential market of $2.1 Billion in the US alone. Candesant's first product is a non-invasive energy device that temporarily inactivates sweat glands and significantly reduces sweating for up to two months after a single treatment. The product will be marketed to dermatologists and other aesthetic physicians for use in a no-downtime procedure that takes less than 15 minutes in the office. Ms. Hunt has guided the company through product development, pre-clinical studies and early clinical testing. Candesant recently closed an oversubscribed Series A financing led by blue chip investors including Polaris Partners.
Prior to founding Candesant Biomedical, Ms. Hunt served as the Senior Vice President of Commercial Development for Revance Therapeutics (NASDAQ: RVNC) which she joined in 2009. Ms. Hunt was instrumental in taking the company public in February 2014; raising over $110 million in the offering which was oversubscribed by more than 10X and completed a secondary offering six months later raising $140 million. In addition, Ms. Hunt guided all the commercial activities for the company’s product candidates: RT001, the first topically applied botulinum toxin (BoNTA) product and RT002, the first injectable BoNTA to show significantly longer duration of action compared to Botox®, the market leader.
John Koconis is a highly accomplished strategic and operational leader with over 25 years of experience in the pharmaceutical sector focused on broad, specialty and rare/orphan dermatology development and commercialization. He brings a unique perspective having led successful teams in global markets and launched multiple market-leading products. John currently serves as the CEO of Timber Pharmaceuticals, a development stage company focused on treatments within orphan/rare dermatology. Previously, he served as CCO at Castle Creek Pharmaceuticals, a specialty dermatology company focused on orphan diseases. John also served as the global lead for dermatology and respiratory disease at Sanofi Genzyme, where he supported the global launch of Dupilumab, and held various roles with LEO pharma over 15 years, where he led the establishment of the company’s U.S. presence as president and CEO and launched multiple products into the American market.
Dr. Paul F Lizzul, a physician scientist and entrepreneur, is the Chief Medical Officer of AnaptysBio leading the company’s development organization, including clinical development, clinical operations, regulatory affairs, data sciences, medical affairs, clinical pharmacology and toxicology. Prior to joining AnaptysBio, he held positions in diverse organizations including Global Development Lead for Inflammation at Amgen, Chief Medical Officer of Sienna Biopharmaceuticals and Senior Medical Director at Kythera Biopharmaceuticals. Dr. Lizzul is also a volunteer faculty member in the division of dermatology at the David Geffen School of Medicine at UCLA. Prior to transitioning into biotech leadership roles Dr. Lizzul was an Assistant Professor of Dermatology and Associate Director of Clinical Research at the Tufts Medical Center. He is a board-certified dermatologist, a faculty member of the American Academy of Dermatology and has also served on the United States Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee. Dr. Lizzul received his M.D., Ph.D. in molecular genetics and M.P.H. in epidemiology from the Robert Wood Johnson Medical School at Rutgers. He has also earned an M.B.A. in entrepreneurship from the Rutgers Business School.
Dr. Mackay has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. Prior to founding Aristea, he was President and Chief Executive Officer of Ardea Biosciences, Inc., following the company's acquisition by AstraZeneca in 2012. James was instrumental to setting up an innovative model for Ardea Biosciences that retained the biotech's independence and accountability for the development of the gout franchise while also developing a synergistic and collaborative relationship with the parent company, AstraZeneca. Prior to Ardea, James held senior executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas. and managed significant global functional departments.
As well as being an advisor to Arthrosi Therapeutics, James is an independent Board member for both MatriSys BioScience and Privo Technologies.
Additionally, James plays a pivotal role in the San Diego Ecosystem and currently sits on the Board and Executive Committee of CONNECT as well as being Vice-Chair of CONNECT. He also sits on the Board of BIOCOM. He is a former Board member of the San Diego Economic Development Corporation (EDC). James holds a BS in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.
Dr. Douglas Maslin, is Senior Director and Clinical Lead at Evelo Biosciences. Douglas is responsible for the clinical strategy and execution of the EDP1815 and EDP1867 programs, which encompass studies in atopic dermatitis, psoriasis, and COVID-19.
Prior to joining Evelo, Douglas was a practicing physician in both the Dermatology and Clinical Pharmacology and Therapeutics departments at Addenbrooke's Hospital, Cambridge, UK. He has a special interest in psoriasis, atopic dermatitis, and clinical trials.
Douglas graduated with distinction from Cambridge University in both his undergraduate and graduate programs. He has since received 6 national and international dermatology scholarships and prizes.
Catherine Mazzacco is a pioneering leader who joined LEO Pharma as President and CEO in August 2019. She is an accomplished executive with more than 25 years of experience in international business management, strategy, marketing and sales within the pharmaceutical and life science industries. Her major achievements include the successful launch and expansion of biologics in the immunology therapeutic area. Catherine’s wealth of professional and business experience includes positions as head of Global Commercial Operations for GE Healthcare Life Sciences BioPharma division, and, before that, numerous leadership positions at Abbott/AbbVie Inc. in the pharmaceutical, diagnostic and medical devices divisions. Catherine is known for her dedication to patients as well her strategic vision and ability to inspire teams to challenge the status quo. She earned her Bachelor of Science in Engineering, with a concentration in Option Biotechnology, from University of Compiègne. Catherine is a member of the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Lloyd S. Miller, M.D., Ph.D., joined Janssen Immunology in January 2020 as Vice President, Immunodermatology Disease Area Stronghold (DAS) Leader. In this role, Dr. Miller's primary objective is to drive the scientific leadership in dermatology and set the strategy to meet the needs of millions of patients living with immune-mediated skin diseases who have inadequate available treatments. In this role, he serves as a member of the Janssen Immunology Core Leadership Team and Immunology Portfolio Committee and is based in Spring House, Pennsylvania.
Dr. Miller earned his B.A. in biology at Johns Hopkins University and received his M.D. and Ph.D. degrees from the State University of New York Downstate Medical Center in Brooklyn. His dermatology residency and post-doctoral research fellowship were completed in the Specialty Training and Advanced Research (STAR) program at the University of California Los Angeles (UCLA). At UCLA, he started his basic science and translational research program that involved the study of skin infections and inflammation, the skin microbiome and wound healing responses. In 2012, Dr. Miller moved his research program to the Johns Hopkins Department of Dermatology, where he served as Vice Chair for Research in Dermatology and Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine. Over the years, Dr. Miller has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given over 75 oral presentations at national and international scientific programs and meetings. In addition, he has received several NIH grants, in addition to private foundation and industry funding awards for his research. Throughout his career, he practiced both general dermatology and specialized wound Care.
Dr. Miller also served as a standing roster member on the Arthritis, Connective Tissue and Skin (ACTS) NIH study section, the Medical and Scientific Review Committee for the Dermatology Foundation, the Scientific Program Committee for the Society for Investigative Dermatology and was elected to the American Society of Clinical Investigation. He is certified by the American Board of Dermatology.
Dr. Flemming Ørnskov, MD, MPH was appointed as Galderma’s Chief Executive Officer in October 2019.
Immediately prior to joining Galderma, Flemming served as Chief Executive Officer of Shire plc from 2013 to 2019. His reputation as a visionary leader in the pharmaceutical industry was built through positions as Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer; Global President, Pharmaceuticals and OTC Bausch & Lomb Inc.; first Chairman then CEO of Lifecycle Pharma A/S (now Veloxis); President and CEO of Ikaria Inc.; and President of Ophthalmology at Novartis. Flemming is currently also acting as non-executive Chairman of Recordati S.p.A and Centogene, and as Director at Waters Corporation.
Flemming holds a Doctor of Medicine from the University of Copenhagen Medical School, a Master of Public Health (MPH) from Harvard University School of Public Health and an MBA from INSEAD.
Mr. Peña has more than 30 years of biotech and pharmaceutical experience with a proven track record of success in the global development of diverse products across multiple therapeutic areas. Luis is a strategic thinker focused on defining clear business objectives and instilling a sense of urgency for driving the success of companies ranging from startups to large established pharmaceuticals. Luis has driven multiple project approvals of global programs across various therapeutic areas including dermatology, immunology, cardiology and anti-infectives. Luis was a co-founder of Dermira and served as Chief Development Officer, where he headed the R& D group. Prior to joining Dermira, Luis served as Vice President, Head of Global Prescription Development at Stiefel, a GSK company, and was Senior Vice President Portfolio Planning and Management at Stiefel Laboratories prior to its acquisition by GlaxoSmithKline, Inc. He also held leadership roles in portfolio management and product development at Connetics and Theravance, Inc. as well as various leadership positions in manufacturing and research and development at Genentech, Inc. Luis holds a B.S. in biochemistry from San Francisco State University.
Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences. Roivant is focused on developing transformative medicines faster by building technologies and deploying talent in creative ways. Roivant has developed over 40 medicines and has completed 8 successful phase 3 studies across its family of companies, including most recently in psoriasis. Mr. Ramaswamy graduated summa cum laude in Biology from Harvard College and began his career as a successful biotech investor at QVT Financial. He continued to work as an investor while earning his law degree at Yale Law School, where he was a recipient of the Paul & Daisy Soros Fellowship. He was born and raised in Cincinnati, Ohio. In 2020, Mr. Ramaswamy served on Ohio’s coronavirus task force. Mr. Ramaswamy also serves on the board of The Foundation for Research on Equal Opportunity, a nonpartisan think tank focused on expanding economic opportunity to those who least have it. In 2020, he emerged as a prominent national commentator on issues including the future of capitalism and shared American identity, appearing on Fox Business, Tucker Carlson Tonight, and other forums. He has published op-eds appearing in The Wall Street Journal, The New York Times, Newsweek, and other venues. Mr. Ramaswamy is the author of the forthcoming book Wokenomics: Inside Corporate America’s Social Justice Scam to be published by Hachette Book Group in summer 2021.
Sanuj K. Ravindran, M.D. is the CEO of PellePharm Inc., and also serves as executive chairman of Phoenix Tissue Repair. Both companies are affiliates of BridgeBio Pharma (BBIO), where Dr. Ravindran is a CEO-in-residence, focused on rare and genetic skin diseases.
Dr. Ravindran has more than 18 years of strategic and operational biopharma experience. Previously, he was chief business officer at aTyr Pharma (LIFE), a clinical stage rare disease-focused biotechnology company, where he led corporate strategy, financial strategy, business development, and investor relations. Prior to that, he was senior vice president of corporate development for The Medicines Company (MDCO). Initially a practicing physician, Dr. Ravindran began his biopharma career as a venture capitalist for 10 years with Burrill & company, Radius Ventures, and Asian Healthcare Fund.
Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. He received a B.A. from Northwestern University, his M.D. from Jefferson Medical College, and his MBA from the Kellogg School of Management.
Dr. Wardwell-Scott, Ph.D., is Vice President of Corporate Development and the Global Head of the EDP1815 Program, as well as a member of the leadership team at Evelo Biosciences. In her current role, Leslie's responsibilities span Business Development, special projects, and integration of strategy. Prior to joining Evelo, Leslie completed her Ph.D. in the Biological and Biomedical Sciences Program at Harvard Medical School where she focused on microbiology and immunology. While working on her Ph.D., Leslie worked as a Senior Business Development Fellow with the Office of Technology Development at Harvard Medical School, and as an Entrepreneurial Fellow at Flagship Pioneering.
Josh Thornton is a founding member of the Healthcare practice at Centerview Partners. He is an experienced advisor to senior management teams and boards of public and private life sciences companies. Over the course of his career he has engaged with life sciences clients across biopharma, medical devices, diagnostics and tools on a broad range of complex strategic and financial issues and transactions, including mergers, acquisitions, divestitures, partnerships, defense, and debt and equity financings.
Mr. Thornton's recent notable transactions include MyoKardia's $13.1 billion sale to Bristol Myers Squibb, AveXis' $8.7bn sale to Novartis, Momenta's $6.5bn sale to Johnson & Johnson, Principia's $3.7bn sale to Sanofi, Audentes Therapeutics' $3.0 billion sale to Astellas Pharma and Portola Pharmaceuticals’ $1.6bn sale to Alexion Pharmaceuticals.
Other notable transactions include Pfizer's $68 billion acquisition of Wyeth, InterMune's $8.9 billion sale to Roche, Receptos' $7.8 billion sale to Celgene, OSI Pharmaceuticals' $4.0 billion sale to Astellas Pharma, Thoratec's $3.7 billion sale to St. Jude Medical, Avanir's $3.5 billion sale to Otsuka, Biogen Idec's $3.25+ billion acquisition of full rights and control of Tysabri from Elan, Pacific Biosciences' $1.3 billion sale to Illumina, MAP Pharmaceuticals' $958 million sale to Allergan, Bioverativ's acquisition of True North Therapeutics for up to $825mm, Haemonetics' $551 million acquisition of assets from Pall Corporation, XenoPort's $457mm sale to Arbor Pharmaceuticals, Ultragenyx's $151mm acquisition of Dimension Therapeutics, Dendreon Corporation's sale of a royalty interest to CPPIB, and Cytokinetics's sale of a royalty interest to Royalty Pharma.
Mr. Thornton joined Centerview in 2009 from Merrill Lynch where he worked in the Mergers & Acquisitions Group. He holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics/East Asian Studies from Wesleyan University.
Dr. Wagner founded Forte, has served as President and Chief Executive Officer of Forte since 2018, and has served as a member of Forte's board of directors since 2017. In 2017, Dr. Wagner was the Head of Corporate Strategy and Development at CANBridge Life Sciences. From 2014 to 2017, Dr. Wagner was the Chief Financial Officer of Pfenex Inc., a biotechnology company. From 2006 to 2014, Dr. Wagner held the positions of Director and Portfolio Manager/Sr. Equity Analyst with Allianz Global Investors, where he was responsible for biotechnology and pharmaceutical investments. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, a biopharmaceutical company from 2005 until 2006. Prior to PDL BioPharma, Dr. Wagner held the position of Vice President at Lehman Brothers starting in 1999 until 2005. Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology.
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 25 years of clinical, research, commercial, strategic and transactional experience. She has worked with diverse organizations including start- ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall's Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Frederick C. Beddingfield III is a physician-scientist and biotech entrepreneur. He is currently the CEO and a director of Kira Pharmaceuticals, a development stage complement therapeutics biotech company focused on immunology, inflammation, and immuno-oncology. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he served in various roles including the Therapeutic Area Head of Dermatology and Chief Medical Officer Allergan Medical. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox (cosmetic, hyperhidrosis, spasticity, and other), Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. Frederick has led four successful FDA advisor committees.
Since completing his training, Frederick has maintained a clinical and teaching practice on the faculty at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children's Skin Disease Foundation and Camp Wonder. He is on the board and co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He had an active clinical practice for seventeen years and remains board certified in dermatology. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Walker co-founded Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc. (NASDAQ: ALDX), a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.
Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).
He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
The networking lounge within the virtual meeting platform will be open to all attendees on the day of the event. Attendees can network via chat features and message board.
Conference virtual platform login page
Enhanced networking opportunities through the Inova One-on-One Partnering platform are available with Premium Registration. The platform allows attendees to communicate directly with companies and other attendees who opt-in
and schedule one-on-one meetings via video conference.
Inova One-on-One Partnering login page
For a PDF tutorial, click here
To view a video demonstration, click here
The current program agenda can be found here.
As an attendee you will be able to enjoy a unique, interactive experience from the comfort and convenience of your home or office. To make sure you are ready to go please review the following documents:
Basic Registration benefits include:
Premium Registration benefits include all basic plus:
All companies who would like to sponsor the 2021 Virtual Dermatology Summit should provide a signed contract no later than December 11, 2020 in order to have a virtual presence. Branding and booth deliverables are required by the platform provider no later than December 18th in order to be included.
If you are interested in a sponsorship opportunity, please contact Erin Conner at firstname.lastname@example.org, for the sponsorship overview and level pricing.
Please check back for confirmed speaker deliverables or contact email@example.com
The Inova One-on-One Partnering platform will launch in December and you will receive an email at that time with instructions on how to access the platform and set up 1:1 meetings.
Requests for registration fee cancellations for the conference must be received on or before December 18, 2020. At the discretion of the conference organizers, a refund via the method of original payment, minus a $75 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 18, 2020. Written notice of your cancellation should be sent to firstname.lastname@example.org.
No damages or refunds shall be due for a failure of performance or because of a delay or cancellation of one or more of the AID Initiatives by the occurrence of any contingency beyond the reasonable control of Host. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, strikes, labor disputes, picketing or work stoppage (actual or threatened), an epidemic, pandemic or disease, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, change in virtual meeting platform ownership or management company, technology updates to the virtual meeting platform, interruptions or failure of the Internet, accessibility, connectivity or network connections, or any other acts beyond the reasonable control of the responsible parties.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.